At the same time, NGS can also detect the ctDNA and cfDNA in the blood to predict the therapeutic effect and drug resistance mechanism of the drug, thereby improving the prognosis of patients with ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.